The single small trial reported symptom improvement in approximately 60% of participants (pain reduction, fatigue improvement, better sleep), but without a placebo control or sham-injection group, attribution of benefit to the cell therapy versus natural fluctuation or expectancy is impossible. Real-world success rates remain unknown.
Only 1 completed trial and 0 actively recruiting trials are registered specifically for fibromyalgia cell therapy, reflecting the early, exploratory stage of this application. That single published study involved placental MSC infusion in a small cohort (n≈20–30) and reported modest improvements in pain scores (average 20–30% reduction on visual analogue pain scale) and some improvement in fatigue severity. Biochemical markers of inflammation (IL-6, TNF-α) showed trending reductions. No control arm was present, and long-term follow-up was not reported.
Sunt un candidat? → · Fibromyalgia & Chronic Fatigue: full overview → · Cost Fibromialgie și Sindromul Oboselii Cronice → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită